Beta Bionics (NASDAQ:BBNX) Cut to “Sell” at Wall Street Zen

Beta Bionics (NASDAQ:BBNX) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Sunday.

Other equities analysts have also recently issued reports about the stock. TD Cowen assumed coverage on shares of Beta Bionics in a research report on Monday, January 26th. They issued a “hold” rating and a $17.00 price objective for the company. UBS Group raised Beta Bionics to a “strong-buy” rating in a research report on Monday, February 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Beta Bionics in a report on Monday, December 29th. Lake Street Capital set a $20.00 price objective on Beta Bionics in a research note on Wednesday, February 18th. Finally, Truist Financial dropped their price objective on Beta Bionics from $37.00 to $25.00 and set a “buy” rating on the stock in a report on Monday, February 2nd. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $23.20.

Beta Bionics Trading Down 6.6%

NASDAQ BBNX opened at $10.76 on Friday. The stock has a market cap of $477.53 million, a P/E ratio of -5.52 and a beta of 5.60. The company’s fifty day simple moving average is $13.06 and its 200-day simple moving average is $21.40. Beta Bionics has a 52 week low of $8.89 and a 52 week high of $32.71.

Beta Bionics (NASDAQ:BBNX) last released its quarterly earnings results on Tuesday, February 17th. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.12. Beta Bionics had a negative net margin of 73.02% and a negative return on equity of 20.29%. The business had revenue of $32.12 million during the quarter.

Insider Activity

In other news, insider Mike Mensinger sold 2,200 shares of the business’s stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $30.10, for a total value of $66,220.00. Following the completion of the sale, the insider owned 80,752 shares of the company’s stock, valued at approximately $2,430,635.20. The trade was a 2.65% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Stephen Feider sold 20,000 shares of the company’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $29.53, for a total transaction of $590,600.00. Following the completion of the sale, the chief financial officer owned 42,614 shares in the company, valued at approximately $1,258,391.42. This trade represents a 31.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 34,705 shares of company stock valued at $945,653 in the last three months.

Institutional Trading of Beta Bionics

Several institutional investors and hedge funds have recently bought and sold shares of BBNX. GPS Wealth Strategies Group LLC lifted its holdings in Beta Bionics by 45.0% during the 3rd quarter. GPS Wealth Strategies Group LLC now owns 1,450 shares of the company’s stock worth $29,000 after buying an additional 450 shares during the last quarter. Summit Securities Group LLC bought a new stake in shares of Beta Bionics in the 4th quarter valued at approximately $52,000. Caitong International Asset Management Co. Ltd increased its holdings in shares of Beta Bionics by 1,075.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock valued at $61,000 after acquiring an additional 1,818 shares during the last quarter. EverSource Wealth Advisors LLC raised its position in shares of Beta Bionics by 203.6% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock valued at $47,000 after acquiring an additional 1,594 shares in the last quarter. Finally, Strs Ohio acquired a new stake in shares of Beta Bionics during the 1st quarter valued at approximately $29,000.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.